{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:13Z","timestamp":1787026993910,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease (CAD), atrial fibrillation (AF)] has been observed in HCV seropositive patients. On the other hand, an increased bleeding risk is another clinical issue, particularly in subjects with liver cirrhosis, gastroesophageal varices, portal hypertension, thrombocytopenia and alcohol consumption. The introduction and progressively greater use of direct-acting antivirals (DAAs) (instead of protease and polymerase inhibitors) during the last decade has enabled a sustained virological response to be achieved in a significant percentage of patients. However, due to the high cardiovascular risk profile in HCV-infected patients, the concomitant use of antithrombotic therapies is often required, bearing in mind the possible contraindications. For example, despite better pharmacokinetic and pharmacodynamic properties compared with vitamin K-antagonists, plasma level fluctuations of direct oral anticoagulants (DOACs) due to pathological conditions (e.g. chronic kidney diseases or hepatic cirrhosis) or drug-drug interactions (DDIs) may be of great importance as regards their safety profile and overall clinical benefit. We aimed to examine and briefly summarize the significant DDIs observed between antithrombotic and HCV antiviral drugs.<\/jats:p>","DOI":"10.3389\/fphar.2022.916361","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T02:41:30Z","timestamp":1660012890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report"],"prefix":"10.3389","volume":"13","author":[{"given":"Mario Enrico","family":"Canonico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Damiano","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Scudiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40261-020-00962-y","article-title":"Drug-drug interactions between direct oral anticoagulants and hepatitis C direct-acting antiviral agents: Looking for evidence through a systematic review","volume":"40","author":"Bellesini","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.lanepe.2021.100222","article-title":"Antithrombotic therapy in patients with liver disease: Population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","volume":"10","author":"Chang","year":"2021","journal-title":"Lancet Reg. Health. Eur."},{"key":"B3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/1060028016660325","article-title":"Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin","volume":"50","author":"De Carolis","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B5","unstructured":"2009"},{"key":"B6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64s","article-title":"Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3350\/cmh.2020.0180","article-title":"Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis","volume":"27","author":"Hsu","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/cpt.1099","article-title":"Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel","volume":"105","author":"Itkonen","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B11","year":"2015"},{"key":"B12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40262-013-0053-x","article-title":"Telaprevir: Clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions","volume":"52","author":"Kiang","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: A systematic review, meta-analysis, and modelling study","volume":"4","author":"Lee","year":"2019","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","volume":"48","author":"Liu","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CPAA.S47895","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"6","author":"Nagelschmitz","year":"2014","journal-title":"Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2021.05.015","article-title":"Orodispersible ticagrelor in acute coronary syndromes: The TASTER study","volume":"78","author":"Parodi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1055\/s-0041-1726298","article-title":"Single, dual, and triple antithrombotic therapy in cancer patients with coronary artery disease: Searching for evidence and personalized approaches","volume":"47","author":"Santoro","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07322-2","article-title":"Dual antiplatelet therapy with 3rd Generation P2Y12 inhibitors in STEMI patients: Impact of body mass index on loading dose-response","volume":"17","author":"Scudiero","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e016441","DOI":"10.1161\/JAHA.120.016441","article-title":"Platelet reactivity in hepatitis C virus-infected patients on dual antiplatelet therapy for acute coronary syndrome","volume":"9","author":"Scudiero","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e012914","DOI":"10.1161\/JAHA.119.012914","article-title":"Risk of new-onset atrial fibrillation among asian chronic hepatitis C virus carriers: A nationwide population-based cohort study","volume":"8","author":"Yang","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","article-title":"In vitro evaluation of potential drug-drug interactions with ticagrelor: Cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab. Dispos."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.916361\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T02:41:32Z","timestamp":1660012892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.916361\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":21,"alternative-id":["10.3389\/fphar.2022.916361"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.916361","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"916361"}}